Tags

Type your tag names separated by a space and hit enter

Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
Drugs Today (Barc). 2010 Jul; 46(7):463-71.DT

Abstract

Intramuscular paliperidone palmitate is a long-acting atypical antipsychotic, which is currently marketed in the U.S. for the acute and maintenance treatment of schizophrenia in adults. Paliperidone is the active 9-hydroxy metabolite of risperidone. After intramuscular injection, paliperidone palmitate is slowly hydrolyzed to paliperidone with a mean half-life of 24-49 days, depending on the dose. Four randomized, double-blind, placebo-controlled trials of 9-13-weeks duration, demonstrated the efficacy of paliperidone palmitate (25-150 mg equivalents [eq.]) in improving the symptoms of acute exacerbation of schizophrenia. As maintenance therapy, paliperidone palmitate (25-100 mg eq.) was significantly more effective than placebo in delaying the time to first relapse in stable schizophrenia patients. Overall, paliperidone palmitate was shown to be well tolerated. It is available as prefilled syringes embracing a wide dose range (25, 50, 75, 100 and 150 mg eq.), and requires no refrigeration, reconstitution or oral antipsychotic supplementation.

Authors+Show Affiliations

Crewe, Cheshire, UK. scientific.prousjournals@thomsonreuters.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20683501

Citation

Owen, R T.. "Paliperidone Palmitate Injection: Its Efficacy, Safety and Tolerability in Schizophrenia." Drugs of Today (Barcelona, Spain : 1998), vol. 46, no. 7, 2010, pp. 463-71.
Owen RT. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. Drugs Today (Barc). 2010;46(7):463-71.
Owen, R. T. (2010). Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. Drugs of Today (Barcelona, Spain : 1998), 46(7), 463-71. https://doi.org/10.1358/dot.2010.46.7.1514647
Owen RT. Paliperidone Palmitate Injection: Its Efficacy, Safety and Tolerability in Schizophrenia. Drugs Today (Barc). 2010;46(7):463-71. PubMed PMID: 20683501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. A1 - Owen,R T, PY - 2010/8/5/entrez PY - 2010/8/5/pubmed PY - 2010/12/16/medline SP - 463 EP - 71 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today (Barc) VL - 46 IS - 7 N2 - Intramuscular paliperidone palmitate is a long-acting atypical antipsychotic, which is currently marketed in the U.S. for the acute and maintenance treatment of schizophrenia in adults. Paliperidone is the active 9-hydroxy metabolite of risperidone. After intramuscular injection, paliperidone palmitate is slowly hydrolyzed to paliperidone with a mean half-life of 24-49 days, depending on the dose. Four randomized, double-blind, placebo-controlled trials of 9-13-weeks duration, demonstrated the efficacy of paliperidone palmitate (25-150 mg equivalents [eq.]) in improving the symptoms of acute exacerbation of schizophrenia. As maintenance therapy, paliperidone palmitate (25-100 mg eq.) was significantly more effective than placebo in delaying the time to first relapse in stable schizophrenia patients. Overall, paliperidone palmitate was shown to be well tolerated. It is available as prefilled syringes embracing a wide dose range (25, 50, 75, 100 and 150 mg eq.), and requires no refrigeration, reconstitution or oral antipsychotic supplementation. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/20683501/Paliperidone_palmitate_injection:_Its_efficacy_safety_and_tolerability_in_schizophrenia_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1514647 DB - PRIME DP - Unbound Medicine ER -